CLINICAL TRIALS PROFILE FOR CANNABIDIOL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for cannabidiol
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT04423341 ↗ | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm | Completed | Benign Essential Blepharospasm Research Foundation | Phase 2/Phase 3 | 2020-05-20 | The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone. |
| OTC | NCT04423341 ↗ | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm | Completed | GW Pharmaceuticals Ltd. | Phase 2/Phase 3 | 2020-05-20 | The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone. |
| OTC | NCT04423341 ↗ | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm | Completed | Smith-Kettlewell Eye Research Institute | Phase 2/Phase 3 | 2020-05-20 | The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone. |
| OTC | NCT04423341 ↗ | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm | Completed | Silkiss Eye Surgery | Phase 2/Phase 3 | 2020-05-20 | The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone. |
| OTC | NCT04611347 ↗ | Topical CBD in Joint Arthritis | Recruiting | University of Virginia | Phase 2 | 2020-11-01 | Rationale: CBD is commonly being used as an over-the-counter treatment for arthritis-related pain, however no clinical trial has been performed to establish efficacy. Hypothesis: CBD is more effective than placebo for relieving pain and improving patient-reported outcomes for thumb basal joint arthritis. Study Design: The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects. |
| OTC | NCT05170451 ↗ | Topical CBD for Musculoskeletal Pain | Not yet recruiting | University of Virginia | Phase 2/Phase 3 | 2022-01-01 | Rationale: CBD is commonly being used as an over-the-counter treatment for musculoskeletal pain; however, no clinical trial has been performed to establish efficacy of CBD in humans for musculoskeletal pain. Hypothesis: CBD is more effective than placebo for relieving pain and improving patient-reported outcomes for musculoskeletal pain. Study Design: The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for 2 additional weeks. Patients will apply the CBD or control cream to the affected area twice daily (approximately every 12 hours) for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for cannabidiol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00241592 ↗ | Vaporization as a Smokeless Cannabis Delivery System | Completed | University of California, San Francisco | Phase 1 | 2004-08-01 | A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana. |
| NCT00241592 ↗ | Vaporization as a Smokeless Cannabis Delivery System | Completed | Center for Medicinal Cannabis Research | Phase 1 | 2004-08-01 | A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana. |
| NCT00309413 ↗ | A Clinical Trial on the Antipsychotic Properties of Cannabidiol | Completed | Coordinating Centre for Clinical Trials Cologne | Phase 2 | 2006-03-01 | The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study. |
| NCT00309413 ↗ | A Clinical Trial on the Antipsychotic Properties of Cannabidiol | Completed | Stanley Medical Research Institute | Phase 2 | 2006-03-01 | The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study. |
| NCT00309413 ↗ | A Clinical Trial on the Antipsychotic Properties of Cannabidiol | Completed | University of Cologne | Phase 2 | 2006-03-01 | The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study. |
| NCT00397605 ↗ | Cannabinoids in Bipolar Affective Disorder | Withdrawn | Vancouver General Hospital | N/A | 2006-11-01 | Some people with bipolar disorder who use cannabis (marijuana) claim that it eases the symptoms of depression and mania. There are many chemicals (called cannabinoids) found in cannabis but two particular ones appear to have medicinal (therapeutic) effects. These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These cannabinoids appear to have mood, anxiety, and sedative effects as well as have antipsychotic and anticonvulsant properties. This study will try to find out if these cannabinoids can be of benefit as an add-on treatment in bipolar disorder and what effects it has on thinking power and memory. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cannabidiol
Condition Name
Clinical Trial Locations for cannabidiol
Trials by Country
Clinical Trial Progress for cannabidiol
Clinical Trial Phase
Clinical Trial Sponsors for cannabidiol
Sponsor Name
